Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation

Peter Auguste,1 Alexander Tsertsvadze,2 Joshua Pink,1 Rachel Court,1 Farah Seedat,1 Tara Gurung,1 Karoline Freeman,1 Sian Taylor-Phillips,1 Clare Walker,1 Jason Madan,3 Ngianga-Bakwin Kandala,4 Aileen Clarke1 and Paul Sutcliffe1*

1Warwick Evidence, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK
2Evidence in Communicable Disease Epidemiology and Control, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK
3Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK
4Department of Mathematics and Information Sciences, Faculty of Engineering and Environment, Northumbria University, Newcastle upon Tyne, UK

*Corresponding author

Declared competing interests of authors: Aileen Clarke is Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK, and the Warwick Medical School receive payment for this work. Aileen Clarke is a member of the National Institute for Health Research (NIHR) Health Technology Assessment and Efficacy and Mechanism Evaluation editorial board. Ngianga-Bakwin Kandala and Aileen Clarke are also supported by the NIHR Collaboration for Leadership in Applied Health Research and Care West Midlands at University Hospitals Birmingham NHS Foundation Trust.

Published May 2016
DOI: 10.3310/hta20380
Scientific summary

Accurate diagnosis of latent tuberculosis in three population groups
Health Technology Assessment 2016; Vol. 20: No. 38
DOI: 10.3310/hta20380

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Tuberculosis (TB) is a major cause of morbidity and mortality worldwide. The timely identification and prophylactic treatment of people with latent tuberculosis infection (LTBI) is of public health and clinical importance. Unfortunately, there is no diagnostic gold standard for identification of LTBI. Instead, the available screening tests provide indirect and imperfect information. There are two types of tests in use in the UK: (1) the tuberculin skin test (TST), read at two levels (5 mm and 10 mm) and (2) the interferon gamma release assays (IGRAs).

In this review we updated a previous clinical guideline (CG) [National Collaborating Centre for Chronic Conditions, Centre for Clinical Practice at the National Institute for Health and Care Excellence. *Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for its Prevention and Control. CG117*. London: NICE; 2011. URL: www.ncbi.nlm.nih.gov/books/NBK97852/ (accessed 27 February 2014)] and investigated the clinical effectiveness and cost-effectiveness of screening tests (IGRAs and TST) in LTBI diagnosis in three population groups: children, immunocompromised people and those who have recently arrived in the UK from high-incidence countries. All of these groups are at higher risk of progression from LTBI to active TB.

This review addressed the following questions:

1. Which diagnostic strategy is most clinically effective and cost-effective in accurately identifying latent TB in children?
2. Which diagnostic strategy is most clinically effective and cost-effective in accurately identifying latent TB in people who are immunocompromised?
3. Which diagnostic strategy is most clinically effective and cost-effective in accurately identifying latent TB in people who are recent arrivals from countries with a high incidence of TB?

Methods

Clinical effectiveness

Search strategy

Search strategies included the following main elements: (1) search of electronic bibliographic databases (including MEDLINE, EMBASE, The Cochrane Library, the Science Citation Index and Conference Proceedings Citation Index, Health Economic Evaluations Database) (updated on 2 December 2014); (2) contact with experts in the field; (3) scrutiny of references of included studies and systematic reviews; and (4) screening of manufacturers’ and other relevant websites.

Study eligibility criteria

English-language studies evaluating and comparing the effectiveness of commercially available tests used for identifying people with LTBI were eligible for inclusion in the review.
**Populations**

- Children (both sexes, aged < 18 years, immunocompetent).
- Those who are immunocompromised or at risk of immunosuppression (both sexes, any age, transplant recipients, human immunodeficiency virus (HIV) infection, renal disease, haematological disease, autoimmune disease, recipients of antitumour necrosis factor alpha treatment, steroids or ciclosporins).
- People recently arrived from regions with a high incidence/prevalence of TB (both sexes, any age, immunocompetent, areas with an estimated incidence of \( \geq 40 \) per 100,000).

**Interventions**

Two IGRA:

- QuantiFERON®-TB Gold-in-Tube (QFT-GIT) [old version QuantiFERON®-TB Gold (QFT-G)] (Cellestis/Qiagen, Carnegie, VA, Australia)
- T-SPOT.TB (Oxford Immunotec, Abingdon, UK).

**Comparator**

- TST 5 mm or 10 mm (Mantoux test) alone or plus IGRA (one- or two-step testing).

**Outcomes**

Associations between test results and validity constructs for LTBI:

- progression to active TB
- previous exposure to Mycobacterium tuberculosis ([Zopf 1883] Lehmann and Neumann 1896) (MTB; defined by proximity, duration, geographical location or dose–response gradient)
- people at low risk of MTB infection or healthy populations.

**Studies**

- Randomised controlled trials and retrospective or prospective cohort studies.
- Cross-sectional or case–control studies.

**Economics**

- Decision-analytic models investigating cost-effectiveness.
- Cost studies.

**Exclusions**

- Studies using test results as proxies for LTBI.
- Non-commercial/in-house IGRA, first-generation QFT or tests unavailable in the UK.
- Studies reporting only between-test agreement.

**Study selection, data extraction and quality assessment**

Two independent reviewers screened all identified records. Disagreements were resolved by discussion and recourse to a third reviewer.

Similarly, relevant data were extracted independently and disagreements were resolved by recourse to a third reviewer. For each test, summary parameters (e.g. sensitivity, specificity, diagnostic odds ratios, cumulative incidence ratios, per cent concordance, kappa statistic) with corresponding measures of variability [95% confidence intervals (CIs), \( p \)-value] were extracted or calculated (e.g. using construct validity categories of exposure levels or progression to active TB, when data permitted).

Data synthesis and analysis
Predictive values for IGRAs and TST for progression to active TB (incidence studies), the degree of association of IGRA and TST results with previous exposure to MTB (defined by proximity, duration or dose–response gradient) and the specificity of IGRAs and TST in healthy populations were assessed. We measured concordance/discordance between IGRAs and TST.

Summary effectiveness measures were pooled using a random-effects model. Heterogeneity was determined visually and by the $I^2$ statistic and chi-squared test (two tailed, $p \leq 0.10$). Subgroup analyses (by TST threshold, IGRA type, setting, TB burden and clinical condition) were undertaken to explore heterogeneity. Calculations were performed with MetaDiSc version 1.4 (Unit of Clinical Biostatistics, Ramón y Cajal Hospital, Madrid, Spain) and Stata version 14 (StataCorp LP, College Station, TX, USA).

Cost-effectiveness
A de novo model structured in two stages (decision tree for LTBI diagnosis and infectious disease model) was developed in R (version 3.1.1; The R Foundation for Statistical Computing, Vienna, Austria) to compare the cost-effectiveness of diagnostic strategies. The first stage included pathways following testing for 1 year before entering the second stage – an infectious disease model. Four diagnostic strategies were examined for each population:

- TST alone
- IGRA alone
- combinations of sequential TST and IGRA
- simultaneous testing.

For the infectious disease stage the following states were modelled:

- active TB
- LTBI – treated for LTBI
- LTBI – untreated
- no TB/LTBI – treated for LTBI
- no TB/LTBI – untreated.

Information required to parameterise the model included prevalence, sensitivity and specificity, adverse events, resource use, and costs and utilities. We used clinical information from the review. We used Bayesian Markov chain Monte Carlo methods to estimate study prevalence and test performance, accounting for the underlying prevalence in each of the studies in the evidence base. We then made a further assumption about the relationship between prevalence in the studies and that in the decision population. In the models, we used QFT-GIT results as the base-case values for the analysis.

Resource use and costs were obtained from the cost-effectiveness review, NHS reference costs 2012/13, the NHS drug tariffs and clinical experts. Costs were adjusted to 2012/13 prices. The simulation was run for 100 years with a 3.5% discount rate and from a NHS and Personal Social Services perspective. A utility decrement of 0.15 was applied to Health Survey for England values for people who received treatment for active TB.
Outcomes were expressed as incremental cost-effectiveness ratios (ICERs) for cost per quality-adjusted life-year (QALY) and cost per diagnostic error avoided. Univariate and probabilistic sensitivity analyses were undertaken.

**Results**

**Clinical effectiveness**

We identified 6687 records. After removing duplicates, 3757 records were screened, of which 54 (53 unique studies) were included. We included 37 additional studies from CG117.

The majority of included studies compared the strength of association between QFT-GIT/G IGRA and TST (5 mm or 10 mm) in relation to the incidence of active TB or previous TB exposure (e.g. proximity to, relationship with an active case or weighted contact score). Seven of the 15 incidence group studies had a high risk of bias, six had a moderate risk of bias and two had a low risk of bias. Twenty-nine of the 38 exposure studies were of lower quality.

**Children**

The results of the 27 studies were:

- **Incidence studies:**
  - TST 5 mm: there was no difference between TST 5 mm and QFT-GIT [two studies; pooled ratio of cumulative incidence ratios (R-CIR) 1.12, 95% CI 0.72 to 1.75].
  - TST 10 mm: QFT-GIT was better than TST 10 mm (three studies; pooled R-CIR 4.33, 95% CI 1.32 to 14.23).

- **Sensitivity and specificity:**
  - TST 5 mm: IGRA (QFT-GIT/G) had similar sensitivity (48–100% vs. 57–100%) to and slightly better specificity (49–90% vs. 45–65%) than TST 5 mm.
  - TST 10 mm: IGRA had a higher sensitivity (48–100% vs. 30–56%) and a slightly lower specificity (49–90% vs. 63–93%) than TST 10 mm.

- **Exposure studies:** IGRA performed better than TST 5 mm/10 mm in 14 studies [pooled ratio of diagnostic odds ratios (R-DOR) 1.98, 95% CI 1.19 to 3.28; $I^2 = 89\%$].

- **Subgroup analyses (stratified by TB burden setting):**
  - In low TB burden settings IGRA performed better than TST 5 mm/10 mm (six studies; pooled R-DOR 4.74, 95% CI 2.15 to 10.44).
  - In high TB burden settings there was no difference between the tests (eight studies; pooled R-DOR 1.13, 95% CI 0.78 to 1.65).
Immunocompromised people
The 48 studies were stratified into those including participants with HIV infection, solid organ transplantation, post-kidney transplantation, haemodialysis (end-stage renal disease), immune-mediated inflammatory diseases before antitumour necrosis factor alpha (TNF-α) therapy, hepatitis C and lupus erythematosus. The results of the studies were as follows:

- Incidence studies: in the two studies reporting data, R-CIR estimates were non-significant with wide 95% CIs.
- Exposure studies:
  - IGRAs performed better than TST 5 mm/10 mm in people with:
    - haemodialysis (four studies; pooled R-DOR 2.53, 95% CI 1.48 to 4.34)
    - hepatitis C (one study; R-DOR 8.45, 95% CI 3.71 to 19.24).
  - TST 10 mm performed significantly better than QFT-GIT for people with HIV/acquired immunodeficiency syndrome (AIDS) (two studies; pooled R-DOR 0.35, 95% CI 0.15 to 0.83).
- Subgroup analysis (stratified by condition): R-DOR estimates were non-significant/inconclusive with wide 95% CIs in:
  - people with lupus erythematosus
  - people with immune-mediated inflammatory diseases before antiTNF-α therapy
  - solid organ transplantation candidates
  - kidney transplant recipients.

Recent arrivals from countries with a high incidence of tuberculosis
The results of the 15 studies were:

- Incidence studies:
  - There was no significant difference between TST 5 mm/10 mm and QFT-GIT (two studies; pooled R-CIR 1.57, 95% CI 0.52 to 4.76).
  - There was no significant difference between TST 10 mm and T.SPOT.TB (one study; R-CIR 0.37, 95% CI 0.10 to 1.41).
- Exposure studies: there was no significant difference between TST 10 mm and QFT-GIT (three studies; pooled R-DOR 0.96, 95% CI 0.69 to 1.33).

Cost-effectiveness
Ten relevant studies were identified and all performed well against frameworks for best practice for reporting economic evaluations.

Bayesian meta-analysis of relevant studies gave the following values with 95% credible intervals for use in the models:

- in children:
  - TST (≥ 5 mm): sensitivity 72.80% (60.59% to 72.94%); specificity 49.03% (47.96% to 50.08%)
  - TST (≥ 10 mm): sensitivity 53.51% (38.21% to 67.69%); specificity 74.81% (34.34% to 76.18%)
  - QFT-GIT: sensitivity 68.84% (58.56% to 78.20%); specificity 61.03% (60.30% to 61.76%)
  - T-SPOT.TB: sensitivity 50.00% (2.45% to 97.64%); specificity 77.58% (67.38% to 86.40%).
• In immunocompromised people:
  - TST (≥5 mm): sensitivity 32.42% (11.19% to 58.48%); specificity 74.22% (72.88% to 75.57%)
  - TST (≥10 mm): sensitivity 16.82% (2.52% to 38.99%); specificity 83.97% (78.99% to 88.31%)
  - QFT-GIT: sensitivity 55.48% (24.73% to 83.73%); specificity 82.27% (80.52% to 83.96%)
  - T-SPOT.TB: sensitivity 66.65% (35.17% to 91.44%); specificity 68.46% (63.46% to 73.37%)

• In recently arrived populations:
  - TST (≥5 mm): sensitivity 93.56% (77.86% to 99.77%); specificity 50.11% (47.90% to 52.29%)
  - QFT-GIT: sensitivity 59.15% (35.84% to 81.42%); specificity 79.29% (77.80% to 80.73%)
  - T-SPOT.TB: sensitivity 70.01% (39.78% to 92.42%); specificity 39.92% (34.39% to 45.54%)

Model outputs: incremental cost-effectiveness ratios – cost per quality-adjusted life-year and cost per diagnostic error avoided

• In children:
  - TST (≥5 mm) negative followed by QFT-GIT was the most cost-effective strategy with an ICER of £18,900 per QALY gained.
  - T-SPOT.TB was the most cost-effective strategy with an ICER of approximately £2700 per diagnostic error avoided compared with TST (≥10 mm).

• In immunocompromised people:
  - QFT-GIT negative followed by TST (≥5 mm) was the most cost-effective strategy with an ICER of approximately £18,700 per QALY gained.
  - QFT-GIT positive followed by TST (≥5 mm) was the most cost-effective strategy with an ICER of approximately £300 per diagnostic error avoided compared with TST (≥10 mm).

• In the recently arrived population:
  - TST (≥5 mm) alone was the most cost-effective strategy with an ICER of approximately £1500 per QALY gained compared with QFT-GIT.
  - TST (≥5 mm) positive followed by QFT-GIT was the most cost-effective strategy with an ICER of approximately £700 per diagnostic error avoided compared with QFT-GIT alone.

Discussion

Summary of results

In children the limited evidence suggested that TST 5 mm was the best test for predicting LTBI. TST (≥5 mm) negative followed by QFT-GIT was the most cost-effective strategy.

Interferon gamma release assays appeared to outperform TST in low TB burden settings but not high TB burden settings, a finding that is consistent with a growing body of evidence showing reduced sensitivity and specificity of IGRAs in high TB burden settings. This type of effect modification could be explained by higher frequency of exposure to MTB, different transmission dynamics, malnutrition, comorbidity, coinfection with HIV or helminthic infection.
For immunocompromised people most of the evidence was insufficient and inconsistent. There was large variation in the performance of IGRAs compared with TST across different clinical subgroups. QFT-GIT and T-SPOT.TB performed better than TST 5 mm/10 mm in those undergoing haemodialysis and those with hepatitis C. In contrast, QFT-GIT performed significantly worse than TST 10 mm in people with HIV/AIDS. This observation could potentially be explained by T-lymphocyte depletion. For other clinical subgroups of immunocompromised people the evidence was inconclusive because of the high level of uncertainty around the statistically non-significant effect estimates. The QFT-GIT negative followed by TST (≥ 5 mm) strategy was the most cost-effective in this group with an ICER of approximately £18,700 per QALY.

Among recently arrived people from countries with a high TB burden, there was no significant difference between the performance of IGRAs and the performance of TST in identifying LTBI. The TST (≥ 5 mm) alone strategy was the most cost-effective with an ICER of approximately £1500 per QALY.

**Strengths and limitations**

The findings of this review warrant a cautious interpretation. The evidence was inconclusive, in large part because of unexplained heterogeneity, poor reporting, missing data and great uncertainty around the effect estimates for the association between test results and the constructs of validity for LTBI. With no ‘gold standard’ and an inadequate definition of construct validity for LTBI (e.g. definitions of previous exposure may not represent the true presence of LTBI), exposure misclassification was probably an important issue.

Other factors that may have contributed to this variability are study setting, type of population, type of test, previous bacillus Calmette–Guérin (BCG) vaccination and the limitations of screening tests (inter-/intrarater variability in the interpretation of test results, boosting, conversion, reversion, different cut-offs for test positivity, assay manufacturing, pre-analytical processing and/or incubation delay). Apart from these issues, various sources of methodological bias may have independently distorted the review findings. For example, the study findings may have been biased because of a lack of blinding, selection bias, partial verification bias because of incomplete outcome data assessment and incorporation bias.

The strengths of the cost-effectiveness assessment include the building of a de novo two-stage model and the use of the review findings (coupled with Bayesian meta-analysis) to derive summary estimates of diagnostic accuracy, although we did not adjust for BCG status because of a lack of data. A number of assumptions were made, including that the TST was costed similarly for those that were read and those that were not read. Resource use was estimated with input from our clinical advisors.

**Implications**

The findings should be viewed by clinicians and policy makers cautiously because of the limited evidence, the lack of a gold standard diagnostic test and the assumptions made. Clinicians should be mindful of the variation in performance of the different testing strategies among different populations.

**Research priorities**

- The inconsistent performance of IGRAs in high- and low-TB settings should be investigated to see whether or not it is replicable.
- Prospective studies are needed for people at high risk of TB to assess progression to active TB.
- The relative benefits of two-step testing with different combinations of IGRAs and TST compared with single-step testing should be investigated.
- For retrospective or cross-sectional studies a standard set of component exposures to aid classification into high and low risk for LTBI is needed, alongside identification of more accurate markers of LTBI.
Study registration

This study is registered as PROSPERO CRD42014009033.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.

‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report
The research reported in this issue of the journal was funded by the HTA programme as project number 13/178/01. The contractual start date was in March 2014. The draft report began editorial review in March 2015 and was accepted for publication in September 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2016. This work was produced by Auguste et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
**Health Technology Assessment Editor-in-Chief**

Professor Hywel Williams  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

**NIHR Journals Library Editor-in-Chief**

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

**NIHR Journals Library Editors**

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie  Health Services Research Unit, University of Aberdeen, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

**Editorial contact:**  nihredit@southampton.ac.uk